Leerink Partnrs Forecasts Stronger Earnings for Nanobiotix

Nanobiotix S.A. (NASDAQ:NBTX) – Research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Nanobiotix in a report released on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.94) for the year, up from their prior forecast of ($1.22). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix’s FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.

Nanobiotix Stock Down 4.0 %

NASDAQ NBTX opened at $3.62 on Friday. The firm’s fifty day moving average price is $3.51 and its 200 day moving average price is $3.91. Nanobiotix has a 12 month low of $2.76 and a 12 month high of $7.51.

Institutional Trading of Nanobiotix

A number of large investors have recently bought and sold shares of NBTX. OLD Mission Capital LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth $139,000. Geode Capital Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth $29,000. Jane Street Group LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth $73,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth $39,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.